Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, in cancer cell line models

被引：0
|
作者：
Helu, Xousaen M.
Griffiths, Ellie
Calinisan, Andrew
Hebbert, Allan
Yan, Larry
Hoffman, Natalie
Trinh, David
Hover, Laura
Fernandez-Banet, Julio
Briere, David M.
Lifset, Ella
Olson, Peter
Christensen, James G.
Hallin, Jill
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1943
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1943
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation
    Peng Bai
    Qiuping Zhou
    Pengcheng Wei
    Hua Bai
    Sanny K.Chan
    John W.Kappler
    Philippa Marrack
    Lei Yin
    Science China(Life Sciences), 2021, (12) : 2144 - 2152
  • [22] Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation
    Peng Bai
    Qiuping Zhou
    Pengcheng Wei
    Hua Bai
    Sanny K. Chan
    John W. Kappler
    Philippa Marrack
    Lei Yin
    Science China Life Sciences, 2021, 64 : 2144 - 2152
  • [23] Overcoming Cell Subtype-Specific Adaptive Resistance to KRAS G12D Inhibition in KRAS G12D-Mutant Pancreatic Cancer
    Lin, Qingxiang
    Morales, Alvin
    Barnes, Haley
    Corcoran, Ryan Bruce
    CANCER RESEARCH, 2024, 84 (17)
  • [24] Candidate molecular alterations associated with potential resistance in KRAS G12D gastrointestinal cancers
    Jazieh, Khalid
    Tsai, Jill
    Solomon, Sheila R.
    Xie, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors
    Sun, Ran
    Hu, Yangfan
    Liu, Xiangwen
    Lin, Yingjun
    Lv, Dan
    Li, Wei
    Fu, Lei
    Jiang, Faqin
    BIOORGANIC CHEMISTRY, 2024, 148
  • [26] Discovery of SHR1127, an orally bioavailable, highly potent and selective KRAS G12D inhibitor
    Li, Xin
    Shen, Feng
    Zhang, Limin
    Wang, Wei
    Kong, Luyao
    Bao, Yong
    Mao, Yuchang
    Wang, Zaiyong
    Lin, Sophie
    Zhang, Zhe
    Feng, Jun
    Hu, Min
    He, Feng
    CANCER RESEARCH, 2024, 84 (06)
  • [27] ASPC-1-MRTX-1133R as a useful cell line model for KRASG12D inhibitor development
    Wang, Guoqian
    Tang, Yao
    Lv, Tingduo
    Ning, Jinying
    Hao, Feng
    CANCER RESEARCH, 2023, 83 (07)
  • [28] Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.
    Jazieh, Khalid
    Tsai, Jill
    Zhu, Mojun
    Xie, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 170 - 170
  • [29] ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models
    Nagashima, T.
    Inamura, K.
    Nishizono, Y.
    Suzuki, A.
    Tanaka, H.
    Yoshinari, T.
    Yamanaka, Y.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S30 - S30
  • [30] LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models
    Gong, Xueqian
    Gao, Hong
    Bender, Mark H.
    Ming, Wenyu
    Zhang, Youyan
    Stewart, Trent R.
    Yu, Chun Ping
    Xu, Wei Guo
    You, Aurthur Xintian
    Bian, Wen Ting
    Li, Binghui
    Wang, Tao
    Bian, Huimin
    Tandon, Manuj
    Capen, Andrew
    Cavitt, Rachel N.
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Klippel, Anke
    Iyer, Chandrasekar
    CANCER RESEARCH, 2024, 84 (06)
12345